COSTA MESA, CA – NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that tetrahydrocannabinol (THC) derived from NB1111, the proprietary Nemus prodrug of THC, achieved significant tissue concentrations in multiple compartments of the eye that correlated with the lowering of IOP in a normotensive ocular animal model. The data will be presented on Saturday, June 24th at 1pm EDT at the 2017 ICRS Meeting in Montreal, Canada by the company’s research and discovery partner, the University of Mississippi.
The abstract, “Intraocular pressure lowering efficacy of a Δ9 -tetrahydrocannabinol prodrug, NB1111, in a normotensive rabbit model” expands on previously reported data by showing that Nemus drug candidate NB1111 safely penetrated multiple ocular chambers and concentrated in key tissues that help regulate intraocular pressure. Parallel studies using THC alone under similar testing conditions showed that native THC was unable to achieve concentrations in the eye comparable to NB1111. All studies were conducted in a normal, non-glaucomatous eye. The poster accompanying the abstract will be posted on the Nemus website after the presentation date.
“This set of experiments were important in the development of NB1111 by showing the superiority of NB1111 in both lowering IOP even in a normotensive eye, and the ability to enter the eye versus THC under similar testing conditions and formulations, including the use of a solid lipid nanoparticle (SLN) delivery formulation,” commented Brian Murphy, MD, CEO and Chief Medical Officer of Nemus.
“In addition to lowering IOP, the NB1111 formulations did not display any toxic corneal changes to the eyes of exposed animals,” stated Soumyajit Majumdar, PhD, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research and Graduate Programs in the School of Pharmacy at the university and lead scientist of the ophthalmic studies of NB1111. “The corneal analysis is an important safety finding for this drug as well as a lack of hyperemia that can be seen with some other glaucoma therapies. We look forward to further testing as Nemus prepares to move into human trials.”
“The Nemus ophthalmology platform continues to evolve as we work to develop an NB1111 formulation for human testing. In addition, Nemus and the University have collaborated on developing an analogue of CBD into an eye drop formulation (NB2222). We plan on submitting an abstract to an upcoming scientific meeting to present data on the NB2222 program. The hallmark of many ocular diseases, from glaucoma to macular degeneration, results in damage to the optic nerve. We feel that cannabinoid-based therapies utilizing a prodrug of THC and an analogue of CBD could provide a substantive addition to current treatments across a spectrum of eye diseases related to the neuroprotective attributes of these cannabinoid molecules,” noted Dr. Murphy.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements about the potential benefits of NB1111 and NB2222 and the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.
ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS’ strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.
For more information, visit http://www.nemusbioscience.com.
About the University of Mississippi
The University of Mississippi, the state’s flagship institution, is among the elite group of R-1: Doctoral Universities – Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academics, research and business. Its 15 academic divisions include a major medical school, nationally recognized schools of accountancy, law and pharmacy, and an Honors College acclaimed for a blend of academic rigor, experiential learning and opportunities for community action.